Curr Treat Options Cardio Med (2018) 20:74 DOI 10.1007/s11936-018-0670-7 Imaging (Q Truong, Section Editor) Updates on the Role of Imaging in Cardiac Sarcoidosis Yan Yatsynovich, MD 1 Damian Valencia, MD 1 Mikhail Petrov, MD 2 Juan David Linares, MD 1 Mufti M. Rahman, MD 2 Nathaniel Dittoe, MD 1,3,4,5,* Address 1 Department of Internal Medicine, Kettering Medical Center, Dayton, OH, USA 2 Department of Internal Medicine, Norwalk Hospital, Norwalk, CT, USA 3 Division of Cardiovascular Medicine, Department of Internal Medicine, Kettering Medical Center, Dayton, OH, USA 4 Boonshoft School of Medicine, Department of Internal Medicine, Wright State University, Dayton, OH, USA *,5 Kettering Medical Center, 3535 Southern Boulevard, Dayton, OH, 45429, USA Email: Nathaniel.Dittoe@ketteringhealth.org * Springer Science+Business Media, LLC, part of Springer Nature 2018 This article is part of the Topical Collection on Imaging Keywords Cardiac sarcoidosis I Non-invasive imaging I LGE I CMR I FDG-PET I Hybrid PET-CMR Abstract Purpose of review The non-specific symptom profile and subclinical nature of disease along with variable region of cardiac involvement in systemic sarcoidosis make the diagnosis particularly challenging. The yield of endomyocardial biopsy, a gold standard for diagno- sis, is not high unless coupled with additional imaging modalities to detect regional involvement. This review is focused on highlighting the major recent advances in imaging modalities and diagnosis of cardiac sarcoidosis. Recent findings There has been much interest and increasing research focused on devel- oping newer and improved imaging modalities to establish diagnosis. CMR and 18 F- FDG- PET are now considered imaging modalities of choice in most centers worldwide, but the data comparing both methodologies head-to-head is limited. Nevertheless, novel radio- tracers (i.e. 68 Ga-DOTANOC, 18 F-Flurpiridaz, 13 N-Ammonia) and hybrid combination PET/ CMR imaging are coming to spotlight with improved sensitivity and specificity for earlier detection of myocardial sarcoid. Summary As CMR and PET are showing increased utilization in cardiac sarcoidosis, 201 Th-